P3006 - Novel Utilization of PuraStat Hemostatic Gel in the Management of Gastric Varix

Colin Ly, DO¹, Antony Mathew, MD², Parvez Mantry, MD^3
1Methodist Dallas Medical Center, Arlington, TX; ²Methodist Dallas Medical Center, Dallas, TX; ³Methodist Liver Institute, Dallas, TX

Introduction: The management of variceal hemorrhage, particularly due to gastric varices, is complicated and at times difficult. PuraStat is a novel hemostatic polypeptide hydrogel that can be applied to sites of active bleeding. However, the use of this agent has not been well described in patients with liver disease.

Case Description/Methods: Here we present a case report of a 48-year-old male with decompensated cirrhosis and recurrent bleeding from gastric varices.

Discussion: Conventional therapy using endoscopic cyanoacrylate injection was initially utilized, with incomplete hemostasis. The patient continued to bleed from this gastric varix. During repeat endoscopy, endoscopic cyanoacrylate injection was used again with incomplete hemostasis. PuraStat was used as an adjunct and complete hemostasis was achieved. Interval followup, revealed no further evidence of bleeding or adverse effects related to prior therapy.
Our case highlights one of the many possible uses for PuraStat as a hemostatic agent in patients with liver disease. There is need for further investigation to assess the full potential of PuraStat as a hemostatic agent in patients with liver disease and portal hypertension related bleeding.



Disclosures:


Colin Ly, DO¹, Antony Mathew, MD², Parvez Mantry, MD³. P3006 - Novel Utilization of PuraStat Hemostatic Gel in the Management of Gastric Varix, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.